- Home
- LEU vs ANNX Comparison
LEU vs ANNX Comparison
Compare LEU & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEU
- ANNX
- Stock Information
- Founded
- LEU 1998
- ANNX 2011
- Country
- LEU United States
- ANNX United States
- Employees
- LEU N/A
- ANNX N/A
- Industry
- LEU Mining & Quarrying of Nonmetallic Minerals (No Fuels)
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- LEU Industrials
- ANNX Health Care
- Exchange
- LEU Nasdaq
- ANNX Nasdaq
- Market Cap
- LEU 3.1B
- ANNX 263.3M
- IPO Year
- LEU 1998
- ANNX 2020
- Fundamental
- Price
- LEU $248.52
- ANNX $2.26
- Analyst Decision
- LEU Strong Buy
- ANNX Strong Buy
- Analyst Count
- LEU 10
- ANNX 4
- Target Price
- LEU $171.67
- ANNX $12.50
- AVG Volume (30 Days)
- LEU 1.4M
- ANNX 1.8M
- Earning Date
- LEU 08-05-2025
- ANNX 08-11-2025
- Dividend Yield
- LEU N/A
- ANNX N/A
- EPS Growth
- LEU 40.85
- ANNX N/A
- EPS
- LEU 6.39
- ANNX N/A
- Revenue
- LEU $471,400,000.00
- ANNX N/A
- Revenue This Year
- LEU $3.22
- ANNX N/A
- Revenue Next Year
- LEU $9.91
- ANNX N/A
- P/E Ratio
- LEU $38.86
- ANNX N/A
- Revenue Growth
- LEU 58.72
- ANNX N/A
- 52 Week Low
- LEU $33.51
- ANNX $1.29
- 52 Week High
- LEU $249.14
- ANNX $7.85
- Technical
- Relative Strength Index (RSI)
- LEU 80.15
- ANNX 45.16
- Support Level
- LEU $167.26
- ANNX $2.31
- Resistance Level
- LEU $188.50
- ANNX $2.97
- Average True Range (ATR)
- LEU 14.55
- ANNX 0.27
- MACD
- LEU 4.10
- ANNX -0.05
- Stochastic Oscillator
- LEU 98.95
- ANNX 41.67
About LEU Centrus Energy Corp.
Centrus Energy Corp is engaged in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment has two components which include the sale of separative work units and uranium. The Technical Solutions segment provides engineering, design, and manufacturing services to government and private sector customers. The majority of the firm's revenue is derived from the LEU segment. It has a business presence in the U.S. and other countries, of which prime revenue is generated in the U.S.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.